Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Revenue of $3.14M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts MIRM Hot Sheet
Join SI Premium – FREE
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) reported Q4 revenue of $3.14 million, versus $0 reported last year.
Expect at least $8.0 million in LIVMARLI net product sales in first quarter 2022.
For earnings history and earnings-related data on Mirum Pharmaceuticals, Inc. (MIRM) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- JPMorgan Upgrades Dr. Reddy\'s Laboratories (DRRD:IN) (RDY) to Neutral
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
